U.S. CDC

Center for Disease Analysis Foundation Announces Receipt of an $8 Million Grant from Gilead Sciences to Relink Hepatitis B and C Patients to Care in the United States

Retrieved on: 
Thursday, July 20, 2023

LAFAYETTE, Colo., July 20, 2023 (GLOBE NEWSWIRE) -- The Center for Disease Analysis Foundation (CDA Foundation) announced today that it received an $8 million grant from Gilead Sciences (Nasdaq: GILD) as part of Gilead’s Relink grant program.

Key Points: 
  • LAFAYETTE, Colo., July 20, 2023 (GLOBE NEWSWIRE) -- The Center for Disease Analysis Foundation (CDA Foundation) announced today that it received an $8 million grant from Gilead Sciences (Nasdaq: GILD) as part of Gilead’s Relink grant program.
  • CDA Foundation will disperse the grant to qualifying tax-exempt organizations to contact diagnosed but untreated patients with hepatitis C virus (HCV) or hepatitis B virus (HBV) infection to bring them back into care.
  • Both viruses are responsible for increasing rates of cirrhosis, liver cancer, liver failure and premature deaths.
  • The Relink grant program aims to identify and work to bridge the gaps that remain in linking patients back to necessary care and treatment.

Center for Disease Analysis Foundation Announces Receipt of an $8 Million Grant From Gilead Sciences to Relink Hepatitis B and C Patients to Care in the United States

Retrieved on: 
Thursday, July 20, 2023

The Center for Disease Analysis Foundation (CDA Foundation) announced today that it received an $8 million grant from Gilead Sciences (Nasdaq: GILD) as part of Gilead’s Relink grant program.

Key Points: 
  • The Center for Disease Analysis Foundation (CDA Foundation) announced today that it received an $8 million grant from Gilead Sciences (Nasdaq: GILD) as part of Gilead’s Relink grant program.
  • CDA Foundation will disperse the grant to qualifying tax-exempt organizations to contact diagnosed but untreated patients with hepatitis C virus (HCV) or hepatitis B virus (HBV) infection to bring them back into care.
  • Both viruses are responsible for increasing rates of cirrhosis, liver cancer, liver failure and premature deaths.
  • The relink grant program aims to identify and work to bridge the gaps that remain in linking patients back to necessary care and treatment.

Global Disposable EEG Electrode Market Size, Share & Trends Analysis Report 2021-2028 - ResearchAndMarkets.com

Retrieved on: 
Wednesday, October 6, 2021

The "Global Disposable EEG Electrode Market Size, Share & Trends Analysis Report by Product, by Application (Diagnostic, Therapeutic), by End-use (Hospitals, Clinics), by Region (North America, Europe, APAC, Latin America, MEA), and Segment Forecasts, 2021-2028" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Disposable EEG Electrode Market Size, Share & Trends Analysis Report by Product, by Application (Diagnostic, Therapeutic), by End-use (Hospitals, Clinics), by Region (North America, Europe, APAC, Latin America, MEA), and Segment Forecasts, 2021-2028" report has been added to ResearchAndMarkets.com's offering.
  • Increasing cases of HAIs, technological advancements, and rising prevalence of neurological disorders and Acute Ischemic Stroke (AIS) are the key driving factors for the market.
  • For instance, according to the WHO, in 2016, 15.2 million deaths of the 56.9 million deaths worldwide were due to stroke.
  • In terms of revenue, the disposable needle electrode segment held the largest revenue share in 2020.